HELSINN HEALTHCARE v. TEVA PHARMACEUTICALS Case Brief

Supreme Court of United States • 2019
139 S.Ct. 628

Audio lesson available for this case

LSD+ subscribers can listen to a recorded discussion of this brief - the full facts, holding, and reasoning in audio form.

Unlock with LSD+

Complete case briefs with LSD+

Every LSD.Law brief pairs a full IRAC analysis with opinion summaries at three levels of depth, written by a team of Harvard Law and MIT graduates - a quick synopsis when you are pressed for time, the complete reasoning when you need to go deep.

Adaptive Case Views

Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.

Exam-Ready IRAC Format

We deliver the precise structure professors look for in exam answers.

Complex Cases, Clarified

We break down dense legal reasoning into something digestible, helping you grasp core concepts.

Case Brief Summary & Legal Analysis

4 min read

tl;dr: A company sold its invention under a confidentiality agreement before filing for a patent. The Supreme Court held that this secret commercial sale still qualified as being “on sale” under the America Invents Act, invalidating the later-filed patent.

Legal Significance: The Court affirmed that the America Invents Act (AIA) did not change the pre-AIA standard for the “on-sale” bar. A commercial sale, even if secret, can trigger the one-year grace period for filing a patent application, thus serving as invalidating prior art.

Case Facts & Court Holding

Key Facts & Case Background

Petitioner Helsinn Healthcare developed a drug, Aloxi, to treat chemotherapy-induced nausea. In 2001, Helsinn entered into two agreements with MGI Pharma: a license agreement and a supply and purchase agreement. These agreements granted MGI rights to market and sell specific doses of the drug in the United States and constituted a commercial sale of the invention. While the existence of the agreements was publicly disclosed in press releases and SEC filings, the specific drug dosages—the core of the invention—were kept confidential as required by the agreements. On January 30, 2003, nearly two years after the agreements were executed, Helsinn filed a provisional patent application. A subsequent patent, governed by the Leahy-Smith America Invents Act (AIA), claimed priority to this 2003 date. Respondent Teva Pharmaceuticals later sought to market a generic version of the drug and challenged Helsinn’s patent, arguing it was invalid under the AIA’s on-sale bar because the invention was “on sale” via the 2001 MGI agreements, more than one year before the patent’s effective filing date.

Court Holding & Legal Precedent

Issue: Does an inventor’s commercial sale of an invention to a third party, who is contractually obligated to keep the invention’s details confidential, place the invention “on sale” within the meaning of the America Invents Act’s prior art provision, 35 U.S.C. § 102(a)(1)?

Yes. A commercial sale of an invention to a third party who Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur

Read the full analysis

The complete holding, rule, and analysis for this case are available to LSD+ subscribers.

Start 14-Day Free Trial

IRAC Legal Analysis

Premium Feature Unlock

About IRAC analysis

IRAC (Issue, Rule, Analysis, Conclusion) is the structure professors expect in exam answers. Each LSD.Law brief states the issue, the governing rule with citations, the court's application of that rule, and the conclusion - the same reasoning pattern you will use on exams and in practice.

Legal Issue

Does an inventor’s commercial sale of an invention to a third party, who is contractually obligated to keep the invention’s details confidential, place the invention “on sale” within the meaning of the America Invents Act’s prior art provision, 35 U.S.C. § 102(a)(1)?

Conclusion

This decision clarifies that the AIA did not narrow the scope of Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur

Legal Rule

Under the America Invents Act, an invention is "on sale" for the Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v

Legal Analysis

The Court's analysis centered on the principle of statutory interpretation that when Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labori

Flash-to-Full Case Opinions

Flash Summary

  • The America Invents Act (AIA) did not change the meaning of
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sin

Read the full analysis

The complete holding, rule, and analysis for this case are available to LSD+ subscribers.

Start 14-Day Free Trial